Sanofi has launched its new insulin treatment Toujeo in the UK, and says it will be priced at the same level as its big seller Lantus. The pricing decision matches Sanofi's approach in the US market, ...
Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French drugmaker ...
TIME and Statista have named 500 companies doing best for the Earth Methodology: How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback